Medical Condition

endometrial cancer

Total Trials

25

Recruiting Now

25

Trial Phases

Phase 2, Phase 3, Phase 1, Phase 2

Cancer clinical trials represent the largest single category of recruiting studies worldwide, encompassing everything from early-phase safety studies of novel oncology drugs to large Phase 3 comparisons against current standard-of-care chemotherapy regimens. The field has accelerated dramatically with the rise of immunotherapy, targeted therapies, and CAR-T cell treatments that have transformed outcomes for previously untreatable malignancies.

Trials include checkpoint inhibitors (PD-1/PD-L1 agents), KRAS inhibitors, ADC (antibody-drug conjugates), combination chemotherapy regimens, radiation protocols, and surgical technique comparisons. Many trials stratify by biomarker status (PD-L1 expression, TMB, MSI-H) to identify patients most likely to benefit.

The NCI, pharmaceutical sponsors, and academic cancer centers collectively fund thousands of oncology trials annually across every cancer type.

Frequently Asked Questions — endometrial cancer Clinical Trials

How many clinical trials are currently recruiting for endometrial cancer?

ClinicalMetric currently tracks 25 actively recruiting clinical trials for endometrial cancer, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 25. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.

What trial phases are available for endometrial cancer?

endometrial cancer research spans Phase 1 (7 trials), Phase 2 (3 trials), Phase 3 (2 trials). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.

How do I find out if I qualify for a endometrial cancer clinical trial?

Eligibility criteria for endometrial cancer trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.

Trial Phases

Phase 1

Phase 2

Phase 3

Top Sponsors

Exact Sciences Corporation 1 trial

Alessandro Santin 1 trial

Fondazione Policlinico Universitario Agostino Gemelli IRCCS 1 trial

iOMEDICO AG 1 trial

Genmab 1 trial

endometrial cancer

Frequently Asked Questions — endometrial cancer Clinical Trials

Recruiting Clinical Trials

Endometrial Cancer Vaginal Fluid Specimen Collection Study

Evaluation of Mirvetuximab Soravtansine (IMGN853) in Women With Folate Receptor-α Positive Endometrial Cancer

Robotic-assisted Versus Conventional Laparoscopic Surgery in Obese Patients With Early Endometrial Cancer

Registry Platform Ovarian and Endometrial Cancer

Study to Assess the Efficacy and Safety of Rina-S Compared to Treatment of Investigator's Choice in Participants With Endometrial Cancer

The Better, Harder, Faster, Stronger Study

cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease

The Clinical Utility of DNA Methylation Testing in Patient-collected Urine and Vaginal Samples to Detect Endometrial Cancer: a Case-control Study

Assessing Uterine Cancer Risk in Lynch Syndrome Carriers Using Vaginal Self-sampling and a Health Questionnaire

EIK1005-002: A Clinical Research Study Evaluating EIK1005, a Werner Helicase Inhibitor, as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors Including Microsatellite Instability High (MSI-H) Tumors

Predicting Response to Immunotherapy From Analysis of Live Tumor Biopsies

Phase I Trial Testing the Safety and Tolerability of Chemoradiation Followed by Chemotherapy + Dostarlimab for Stage IIIC, Node Positive, Endometrial Cancer

A Cohort Study of Uterine Malignancies

Vaginal Cuff Brachytherapy Fractionation Study

Randomized Comparison Between Sentinel Lymph Node Biopsy and Lymph Node Dissection in Early Stage Endometrial Cancer

Evaluating Efficacy and Tolerability of Anticancer Drug Therapies for the Treatment of Gynecologic and Breast Cancers

ImpRoving hEalth behaviourS for LIfe After ENdometrial CancEr Trial

Bariatric Surgery for Fertility-Sparing Treatment of Atypical Hyperplasia and Grade 1 Cancer of the Endometrium

A Study of ILB2109 and Toripalimab in Patients With Advanced Solid Malignancies

SLV-154 Treatment of Metastatic Solid Tumors

A Study of PARG Inhibitor IDE161 in Participants With Advanced Solid Tumors

Leveraging Methylated DNA Markers (MDMs) in the Detection of Endometrial Cancer, Ovarian Cancer, and Cervical Cancer

Sentinel Lymph Node Mapping With Different Injection Sites of ICG in Endometrium Cancer

Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors

The Safety, Tolerability, and Efficacy of KD01 in Gynecologic Malignancies